Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06653153 · ClinicalTrials.gov registry record · Phase 3
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
A Phase 3 study of Alzheimers Disease, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 1,400
- Enrollment target
- 20
- Study locations
NCT06653153: Active Phase 3 study of Alzheimers Disease, sponsored by Eli Lilly and Company.
NCT06653153 is a Phase 3 study of Alzheimers Disease that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 1,400 participants, below the 3,917-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06653153, a Phase 3 study of Alzheimers Disease, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.
Primary Outcome
Time to clinically meaningful progression as measured by CDR. CDR is a clinician-rated scale that provides an overall assessment of the participant's stage and degree of impairment across the continuum of early Alzheimer's Disease (AD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Remternetug
Study Locations (20)
California
- Neuro-Pain Medical Center - Fresno
- Care Access - Huntington Beach - Huntington Beach
- Inglewood Clinical - Inglewood
- Irvine Clinical Research - Irvine
- Healthy Brain Clinic - Long Beach
- Riverside Clinical - Riverside
- Clinical Trials Research - Sacramento
- Artemis Institute for Clinical Research - San Diego
- Sharp Neurocognitive Research Center - San Diego
- Ray Dolby Brain Health Center - San Francisco
- The Neuron Clinic - San Marcos - San Marcos
- Syrentis Clinical Research - Santa Ana
- Providence Medical Foundation - Santa Rosa
- California Neuroscience Research, LLC - Sherman Oaks
Arizona
- MD First Research - Chandler - Chandler
- Care Access - 801 South Power Road, Mesa - Mesa
- Banner Alzheimer's Institute - Phoenix
- Banner Alzheimer's Institute Tucson - Tucson
Alabama
- Parkway Medical Center - Birmingham
Colorado
- Care Access - Aurora - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,400 participants |
| Start Date | 2024-10-24 |
| Est. Completion | 2030-10 |
| Phase | Phase 3 |
What the registry record for NCT06653153 still lists
NCT06653153 is an interventional study that assigns participants to a tested intervention. Its 1,400 participants enrollment target places it among the larger protocols in the corpus, below the 3,917-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06653153 names 20 study sites across 4 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT06653153 about?
NCT06653153 is a clinical study titled "A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)". The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-bl...
What is the current status of trial NCT06653153?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,400 participants. The study started on 2024-10-24. Estimated completion is 2030-10.
What conditions does trial NCT06653153 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT06653153?
The interventions under investigation include: Placebo (DRUG), Remternetug (DRUG).
Who is sponsoring clinical trial NCT06653153?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06653153 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06653153's enrollment target sits among peer trials
1,400 11th of 147 higher than 137 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
RECRUITING · Phase 3
-
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02205762 · 1,400 participants · Phase 2
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
- NCT02445222 · 1,400 participants · Phase 3
CAR-T Long Term Follow Up (LTFU) Study
- NCT03145077 · 1,400 participants · NA
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
- NCT04250857 · 1,400 participants
HeartStart FRx Defibrillator Event Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI